Matarin Capital Management’s Myriad Genetics MYGN Stock Holding History

Matarin Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-229,215	Closed	-$6.66M	–	281
2018 Q4	$6.66M	Sell	229,215 -183,978	-45%	-$6.62M	0.54%	73
2018 Q3	$19M	Buy	413,193 +32,588	+9%	+$1.45M	1.23%	8
2018 Q2	$14.2M	Sell	380,605 -18,223	-5%	-$615K	1.03%	19
2018 Q1	$11.8M	Buy	398,828 +14,575	+4%	+$493K	0.88%	32
2017 Q4	$13.2M	Buy	384,253 +335,395	+686%	+$11.3M	1.03%	17
2017 Q3	$1.77M	Buy	+48,858	New	+$1.39M	0.15%	170
2013 Q4	–	Sell	-19,383	Closed	-$456K	–	148
2013 Q3	$456K	Buy	19,383 +2,502	+15%	+$71.1K	0.38%	99
2013 Q2	$454K	Buy	+16,881	New	+$489K	0.46%	91

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Matarin Capital Management's MYGN Position: Q1 2019 in Review

Matarin Capital Management sold out of Myriad Genetics (MYGN) in Q1 2019, closing a stake of 229,215 shares — an estimated $6.66M sold.

Matarin Capital Management first reported a position in MYGN in Q2 2013 and held it in 8 quarters. The position peaked at $19M in Q3 2018. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

Matarin Capital Management reported no remaining Myriad Genetics position as of Q1 2019 after selling out during the quarter.
Matarin Capital Management sold 229,215 Myriad Genetics shares in Q1 2019, an estimated $6.66M.
Matarin Capital Management first reported a position in Myriad Genetics in Q2 2013 and held it in 8 quarters.
Matarin Capital Management's Myriad Genetics position peaked at $19M in Q3 2018.
262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on Matarin Capital Management's 13F filing for Q1 2019, filed 24 Apr 2019.